Texas A&M University could take a leading role in producing a COVID-19 vaccine next year if an effort from Novavax Inc. makes it through clinical trials. The federal government will spend $265 million to reserve a manufacturing center at Texas A&M University System to mass produce a COVID-19 vaccine candidate when clinical trials are complete and approval is granted from the U.S. Food and Drug Administration, system officials said Monday.
Read Again https://www.healthleadersmedia.com/innovation/feds-approve-265-million-manufacture-coronavirus-vaccine-texas-am-facilityBagikan Berita Ini
0 Response to "Feds approve $265 million to manufacture coronavirus vaccine at Texas A&M facility - HealthLeaders Media"
Post a Comment